Compare Abbott Laboratories (ABT) vs Toyota Motor Corp (TM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Toyota Motor Corp — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Toyota Motor Corp trades at $176.06 (market cap $215.62B). The key difference: Toyota Motor Corp is the larger of the two by market cap, and Toyota Motor Corp pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| ABT | TM | |
|---|---|---|
Market Cap | $166.94B | $215.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $248.29 |
52-Week Low | $82.57 | $166.50 |
Enterprise Value | $193.69B | $379.82B |
Dividend Yield | 2.63% | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Toyota Motor (TM) trades at $179.43, up 2.77% today, with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with a P/E of 9.85 and consistent earnings beats, including Q1 2026 EPS of $4.00 versus $3.11 expected. Recent news highlights a $3.6 billion Texas plant expansion to shift Tacoma production from Mexico, signaling strategic US investment. Operating cash flow remains robust at $3.70 trillion for 2025, though net cash flow turned negative due to significant capital expenditures.
Toyota presents a compelling value opportunity with attractive valuation multiples and hybrid vehicle leadership, but faces risks from declining global sales and rising debt levels. Analyst sentiment is mixed with 37.5% buy ratings versus 62.5% hold, reflecting cautious optimism amid competitive pressures. The stock's current technical strength near resistance at $180-183 suggests potential for near-term consolidation before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
